Competition & Markets Authority
CMA warns businesses after ending Remicade investigation
CMA closes investigation into drug firm MSD’s discount scheme.
The Competition and Markets Authority (CMA) has closed its investigation into a suspected anti-competitive discount scheme developed by pharmaceutical company Merck Sharp & Dohme Limited (MSD) after finding no grounds for action.
The CMA found that the discount scheme was designed to delay or reduce competition from other suppliers of infliximab, a drug used to treat chronic illnesses such as Crohn’s disease and rheumatoid arthritis.
After its patent for its infliximab product, called Remicade, expired in early 2015, MSD introduced the discount scheme in an attempt to ensure the NHS would continue to use mostly Remicade, rather than competitors’ newer and cheaper versions of infliximab (known as ‘biosimilars’).
By linking the level of discount offered on Remicade to the total amount of the drug purchased, the scheme - when coupled with caution in the NHS over moving away from tried and tested drugs – was designed to dissuade the NHS from trialling biosimilars, regardless of the potential savings.
If it had been successful, MSD’s discount scheme could have delayed the NHS from benefitting from increased competition and making significant savings on what it spent on Remicade, which, at the time, was over £100 million annually.
In May 2017, the CMA provisionally found that MSD had a dominant market position and that its discount scheme for Remicade, was in breach of competition law, but the case decision group appointed to decide the case has now reached a final decision that there are no grounds for it to take action.
Having considered further evidence, the CMA case decision group has concluded that MSD’s scheme was not, in practice, likely to limit competition from others - the legal test for finding MSD’s conduct to be unlawful. This is because, at the time that the discount scheme was introduced, the market worked differently from the way MSD had envisaged when it designed the scheme.
The CMA’s investigation serves as a warning to businesses which design discount schemes to protect their dominant market position, that they risk breaching UK competition law: had MSD’s scheme in practice been likely to prevent or limit competition from rivals, the company could have faced severe financial penalties.
This case also highlights the rigorous procedures the CMA has in place to ensure that companies under investigation receive a fair hearing, including through the case decision group system, and that the CMA reaches final decisions that take full account of the evidence and arguments before it.
Latest News from
Competition & Markets Authority
Abandonment of cashback websites merger22/03/2019 09:20:00
The CMA has cancelled its merger investigation into TopCashback’s anticipated acquisition of Quidco. This follows the companies’ decision to abandon the transaction.
CMA welcomes Furman Review recommendations13/03/2019 15:15:15
The Competition and Markets Authority (CMA) has welcomed the report submitted today by the Digital Competition Expert Panel to the government.
Guidance on state aid notifications and reporting04/03/2019 17:05:00
Draft procedural guidance on state aid notifications and reporting.
5 office fit-out firms to pay £7 million fine for breaking competition law04/03/2019 11:20:00
Five companies - Fourfront, Loop, Coriolis, ThirdWay and Oakley - have agreed to pay fines totalling over £7 million after admitting being involved in cartel behaviour.
Pharma firms accused of illegal agreements over life-saving drug01/03/2019 09:20:00
The CMA provisionally finds Auden Mckenzie and Waymade broke the law by agreeing not to compete for the supply of hydrocortisone tablets to the NHS.
Abandonment of credit-score checking merger28/02/2019 09:20:00
The CMA has cancelled its merger investigation into Experian’s anticipated purchase of Clearscore.
Reforms proposed to put consumers at the heart of UK competition regime26/02/2019 12:20:00
A major package of proposals to bolster competition and put consumers even more directly at the heart of the CMA’s work was yesterday published.
Sainsbury’s / Asda merger could push up prices and reduce quality21/02/2019 09:20:00
The CMA has provisionally found extensive competition concerns as part of its in-depth investigation of the proposed merger between Sainsbury’s and Asda.